FUJIFILM SonoSite Announces iViz In A Newly Defined High Access Mobility Category

BOTHELL, Wash.--(BUSINESS WIRE)--FUJIFILM SonoSite Inc., the disruptive specialist in designing cutting-edge ultrasound tools and world-leading education for access to point-of-care visualization, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for iViz, its newest medical visualization solution. First commercialized in Europe, iViz was developed from the ground up to meet the needs of the highly-mobile clinician.

“Through iViz, we expand our core mission of increasing access to ultrasound to improve patient care quality and reduce healthcare costs.”

Clinicians do not always treat patients in traditional care settings or have easy access to supporting hospital infrastructure; instead they rely on tools that can easily be carried to help diagnose a patient’s condition. iViz is a powerful new solution for the evolving needs of these point-of-care users. With iViz, clinicians can seamlessly access learning resources and patient information, store exam findings, submit reports, and consult with remote providers for near real-time assessment making it especially suited for field use and for the growing area of telemedicine.

“iViz is a revolutionary solution for clinicians and represents a landmark in FUJIFILM SonoSite’s innovation. It achieves new levels of image performance and provides unprecedented connectivity in a highly mobile platform,” said Masayuki Higuchi, president and CEO of FUJIFILM SonoSite, Inc. “Through iViz, we expand our core mission of increasing access to ultrasound to improve patient care quality and reduce healthcare costs."

iViz is a significant milestone in advancing Fujifilm’s integration of ultrasound with medical IT. As a next generation architecture and platform, iViz is the first medical visualization solution that is enabled for bi-directional EMR connectivity through the Synapse® VNA. Using this option, iViz accepts patient demographics from the EMR eliminating manual entry and saving valuable time. With just a few taps, iViz can also send patient reports to the EMR. Based on the flexible Android OS, the iViz platform will include web-browsing, email and ECG capability.

The system is designed to be highly accessible and light weight. It features a high-resolution, seven-inch display touchscreen, a wide dynamic range, and vibrant color flow images, as well as imaging modes and exams to meet the clinical needs of different medical providers.

To request more information about iViz, visit https://www.sonosite.com/sonosite-iviz.

About Fujifilm

FUJIFILM SonoSite, Inc. is the innovator and world leader in bedside and point-of-care ultrasound, and an industry leader in ultra high-frequency micro-ultrasound technology. Headquartered near Seattle, the company is represented by 26 subsidiaries and a global distribution network in over 100 countries. SonoSite’s portable, compact systems are expanding the use of ultrasound across the clinical spectrum by cost-effectively bringing high-performance ultrasound to the point of patient care. For more information, go to: www.sonosite.com.

FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2015, the company had global revenues of $20.8 billion, at an exchange rate of 120 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.

Contacts

Fujifilm
Lauren Geloso, 914-789-8303
lgeloso@fujifilm.com

Help employers find you! Check out all the jobs and post your resume.

Back to news